Foralumab ( DrugBank: Foralumab )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
96	Crohn disease	1

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029609 (ClinicalTrials.gov)	October 2021	27/8/2021	Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS	A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Multiple Sclerosis	Drug: Intranasal Foralumab Solution;Drug: Placebo	Tiziana Life Sciences, PLC	NULL	Not yet recruiting	25 Years	70 Years	All	55	Phase 1	NULL

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05028946 (ClinicalTrials.gov)	May 1, 2022	24/8/2021	A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease	A Phase IB Multiple Ascending Dose Study of Safety and Tolerability of Orally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: Foralumab	Tiziana Life Sciences, PLC	NULL	Withdrawn	18 Years	70 Years	All	0	Phase 1	NULL